Deepak Sambhara is an Ophthalmology physician. OpenAlex indexes 14 publications with 236 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ocular TherapeutixProgram year202561 paymentsResearch$1,497,139openpaymentsdata.cms.gov ↗
- Apellis Pharmaceuticals, Inc.Program year202536 payments$63,060openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202517 payments$33,587openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
96.5%Antineovascularisation agents95.1%Faricimab-svoa100%Part B, office-administered≥293 patientsComplement Inhibitor1.3%Avacincaptad pegol100%Part B, office-administered≥13 patients+ 3 more classes in this area
Cancer & immunology
3.5%Complement Inhibitor2.3%Pegcetacoplan100%Part B, office-administered≥29 patientsVascular Endothelial Growth Factor Inhibitor1.1%Aflibercept79%Bevacizumab21%Part B, office-administered≥131 patientsDermatology
0%Corticosteroid0%Triamcinolone acetonide100%Part B, office-administered≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Examining Real-World Attrition Among Patients Undergoing Complement Inhibitor Intravitreal Therapy for Geographic Atrophy
Journal of VitreoRetinal Diseases
2026 - Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series
BMJ Open Ophthalmology
2025 - Rates of Prophylactic Ocular Lubrication Administration and Exposure Keratopathy in Adult Patients Admitted to Intensive Care Units of an Academic Medical Center
Investigative Ophthalmology & Visual Science
2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Weinreb, MD
University of California San Diego
Emily Chew, MD
National Eye Institute
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”